Amplyx Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Employees
  • 29
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $91.3M
Latest Deal Amount
  • Investors
  • 24

Amplyx General Information

Description

Developer of antifungal agents intended to treat invasive fungal infections. The company's antifungal agents use both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus and rare molds.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 12730 High Bluff Drive
  • Suite 160
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amplyx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 09-Jan-2020 $91.3M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series B) 28-Feb-2017 000.00 000.00 0000 Completed Generating Revenue
3. Accelerator/Incubator 28-Feb-2017 00.00 Completed Generating Revenue
2. Grant 01-Jan-2017 $11.3M $2.3M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2011 $2.3M $2.3M 000 Completed Generating Revenue
To view Amplyx’s complete valuation and funding history, request access »

Amplyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 8,243,027 $0.001000 8% $0.27 $0.27 1x $0.27 2.04%
To view Amplyx’s complete cap table history, request access »

Amplyx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antifungal agents intended to treat invasive fungal infections. The company's antifungal agents use both in
Pharmaceuticals
San Diego, CA
29 As of 2020
00000
0000 0000-00-00
00000000000 00000

0000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 - 00000

000

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
0000000000000
Manchester, United Kingdom
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amplyx Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Samumed Private Equity-Backed San Diego, CA 000 00000 000000000 - 00000
000 Venture Capital-Backed Manchester, United Kingdom 00 00000 00000000000 00000
000000 00000000000 Private Equity-Backed Copenhagen, Denmark 0000 000000000000
00000 000000000000 Corporation NY 0 00.000 00000000 00.000
0000000 Venture Capital-Backed Wuppertal, Germany 00 000.00 0000000000 000.00
You’re viewing 5 of 28 competitors. Get the full list »

Amplyx Executive Team (15)

Name Title Board Seat Contact Info
Ciara Kennedy Ph.D President, Chief Executive Officer and Board Member
Chris LeMasters Chief Operating Officer
Carlos Sattler Senior Vice President, clinical development
Elizabeth Gordon Ph.D Senior Vice President, Regulatory Affairs
Susan Dubé Vice President of Business Development and Administration
You’re viewing 5 of 15 executive team members. Get the full list »

Amplyx Board Members (12)

Name Representing Role Since
Anand Mehra MD Sofinnova Investments Board Member 000 0000
Edward Mathers Self Board Member 000 0000
Johan Kördel Ph.D Lundbeckfonden Board Member 000 0000
Maha Katabi Ph.D Self Board Member 000 0000
Mark Chin Arix Bioscience Board Observer 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Amplyx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amplyx Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Arix Bioscience Venture Capital Minority 000 0000 000000 0
Generation Ventures (Palo Alto) Venture Capital Minority 000 0000 000000 0
Lundbeckfonden Limited Partner Minority 000 0000 000000 0
Lundbeckfond Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 24 investors. Get the full list »